Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has expanded its network in the US by launching its HOPE range of products for autism sufferers in Louisiana, USA, where laws have recently been expanded to allow more patients access to medical marijuana.
With the passage of ACT No 286, all physicians in the State are now allowed to recommend medical marijuana to any of their patients and make such recommendations for any medical condition.
“High-quality options for patients”
Zelira Therapeutics USA chief executive officer Dr Oludare Odumosu said: “Zelira is committed to delivering high-quality, cannabinoid medicine products and options to patients and physicians in Louisiana.
“Additionally, we remain steadfast in our partnerships across the globe to extend the benefits of HOPE to an even greater patient population while we continue to obtain additional data to enhance our understanding of the impact of medicinal cannabis on patients.”
The HOPE range of products is being manufactured and packaged in Louisiana through a partnership between Ilera Holistic and Southern University’s Agricultural Center and will be available exclusively to all of the State’s licensed medical marijuana pharmacies.
HOPE was launched successfully in Pennsylvania in May 2019 by Ilera Healthcare, which holds the licence for that State.
Other Zelira Therapeutics news
Investors interested in Zelira Therapeutics recently viewed: